# COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

> **NCT04992273** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** casirivimab+imdevimab

## Key facts

- **NCT ID:** NCT04992273
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-13
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Emerging SARS-CoV-2 variants impacting susceptibility to study drug
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04992273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04992273, "COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04992273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*